ArticleACS omega2026
Polysaccharide-Structured Nanoemulgel Matrix Regulates the Co-delivery, Retention, and Biointerface Activity of Amino-Acid-Based Therapeutics in Infected Wound Environments.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study presents a dual-drug water-in-oil (W/O) nanoemulsion developed to encapsulate L-ascorbic acid (AA) and L-lysine (L), enhancing skin regeneration and antimicrobial efficacy. The optimized AA L W/O nanoemulsion has a droplet size of ∼150 nm, a low polydispersity index (<0.35), and a stable zeta potential, with no phase separation during 6 months of accelerated and real-time stability tests. Both AA and L exhibited high encapsulation efficiencies of 94.63 ± 0.38% and 91 ± 0.45%, respectively, which increased further upon incorporation into a tragacanth-based nanoemulgel (97.75 ± 0.91% for AA and 95.13 ± 1.75% for L), due to reduced interfacial drug leakage and enhanced entrapment in the gel matrix. The formulated nanoemulgel significantly decreased bacterial viability and disrupted biofilm, confirmed by crystal violet quantification and FE-SEM imaging. Biological evaluations revealed that the formulated nanoemulgel was noncytotoxic to HaCaT keratinocytes and significantly promoted
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.